Infective endocarditis and outcomes of mitral valve replacement




Anttila Vesa, Malmberg Markus, Gunn Jarmo, Rautava Päivi, Kytö Ville

PublisherWILEY

2021

European Journal of Clinical Investigation

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

EUR J CLIN INVEST

ARTN e13577

51

9

7

0014-2972

1365-2362

DOIhttps://doi.org/10.1111/eci.13577

https://doi.org/10.1111/eci.13577



Background

We investigated the long-term outcomes of mitral valve replacement (MVR) in native mitral valve infective endocarditis (IE).

Methods

Multicentre, population-based cohort register study consisted of 1233 consecutive adult patients treated with first-time MVR in Finland. Mitral valve IE was diagnosed in 170 of these patients. Propensity score matching resulted in 134 pairs with balanced baseline characteristics. The median follow-up was 6.1 years.

Results

Pre-operative native mitral valve IE was associated with an increased hazard of 10-year mortality (38.8% vs 30.5%; HR 2.13; CI 1.17-3.85; P = .013) after MVR. Occurrence of major bleeding was higher in IE patients (26.0%) vs non-IE patients (23.4%) during the 10-year follow-up (HR 2.80; CI 1.01-7.77; P = .048). Hospital admission duration after MVR was longer in IE patients (median 28 vs 11 days; P < .0001). Cumulative ischaemic stroke rate was similar between patient groups (12.1% in IE vs 15.1% in non-IE; P = .493). Re-sternotomy was performed in 13.4% of IE patients and 9.0% of non-IE patients (P = .261).

Conclusions

Patients with native mitral valve IE have a higher risk of death and major bleeding after MVR than matched patients without IE. Results highlight the importance of complication prevention in these patients.



Last updated on 2024-26-11 at 14:00